Myelodysplastic Syndrome (MDS)
What is MDS? A group of disorders in which the bone marrow does not produce enough healthy blood cells. Patients may have anaemia, infection risk or bleeding. Risk is stratified using systems such as IPSS-R, often supplemented by molecular testing.
Drugs used include Vidaza (azacitidine) and Dacogen (decitabine) (hypomethylating agents / HMA).
Treatment approach (overview)
- Consider clinical trial enrolment for all eligible patients
- Supportive care (transfusions, antimicrobials) as needed for all patients
- Lower-risk: ESA, lenalidomide, HMA or IST, or supportive care alone
- Higher-risk: allogeneic transplant when appropriate; HMA as bridge until progression/intolerance
- Hematopoietic growth factors may be used in selected patients
Resources: Leukaemia.org · ELN Guidelines












